Showing results (81-90 of 379) with videos related to
Sort By:
Pageof 38
Cancers|October 23, 2021
Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility StudyAnastasia Kosmou, Christos Sachpekidis, Leyun Pan, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 14, 2017
Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the LiteratureJulia K Winkler, Ralf Gutzmer, Carolin Bender, et al.Cancers|December 23, 2022
Postoperative Radiotherapy and the Role of Regional Lymph Node Irradiation in Localized Merkel Cell Carcinoma: A Single-Center Retrospective AnalysisLisa-Antonia Dinges, Tanja Eichkorn, Sebastian Regnery, et al.European Journal of Nuclear Medicine and Molecular Imaging|November 11, 2017
Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumabHoda Anwar, Christos Sachpekidis, Julia Winkler, et al.Head & Neck|November 13, 2015
Raster-scanned intensity-controlled carbon ion therapy for mucosal melanoma of the paranasal sinusAngela Mohr, Naved Chaudhri, Jessica C Hassel, et al.Oncotarget|May 7, 2016
Which melanoma patient carries a BRAF-mutation? A comparison of predictive modelsThomas Eigentler, Zeinab Assi, Jessica C Hassel, et al.International Journal of Cancer|November 21, 2022
Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry-based investigationsRémi Longuespée, Dirk Theile, Inka Zörnig, et al.European Journal of Nuclear Medicine and Molecular Imaging|July 15, 2023
Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?Christos Sachpekidis, Christoph K Stein-Thoeringer, Annette Kopp-Schneider, et al.Trends in Immunology|December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicitiesRobin Reschke, Ryan J Sullivan, Evan J Lipson, et al.Current Oncology Reports|April 2, 2023
The Latest Option: Nivolumab and Relatlimab in Advanced MelanomaLea Jessica Albrecht, Elisabeth Livingstone, Lisa Zimmer, et al.Pageof 38